Treatment Options for Colorectal Cancer Based on Modified Dukes Classification

Surgical Management by Stage

The American College of Surgeons recommends wide surgical resection with at least 5 cm margins on either side of tumor and removal of lymphatic drainage for early cancer (Dukes A/Stage I) 1, 2
For Dukes B/Stage II (T3-4, N0, M0), surgical resection remains the primary treatment, with consideration of adjuvant therapy for high-risk features, as recommended by the American Society of Clinical Oncology 1, 3
For Dukes C/Stage III (T1-4, N1-2, M0), surgical resection followed by adjuvant chemotherapy is the standard of care, according to the National Comprehensive Cancer Network 1, 3

The American Society of Clinical Oncology strongly recommends adjuvant chemotherapy for all Dukes C (Stage III) patients, as it significantly improves disease-free and overall survival 1, 3, 4
For Dukes B (Stage II) patients, adjuvant chemotherapy may be considered if high-risk features are present, such as T4 tumors, poorly differentiated histology, or vascular invasion, as suggested by the American College of Surgeons 1, 3
High-risk features in Dukes B/Stage II include T4 tumors, poorly differentiated histology, vascular invasion, lymphatic vessel invasion, perineural invasion, obstruction or tumor perforation at presentation, examination of fewer than 12 lymph nodes, and elevated tumor marker levels 1, 3, 5

The National Comprehensive Cancer Network recommends standard adjuvant treatment consisting of fluoropyrimidine-based chemotherapy, which provides a statistically significant survival benefit 1, 3
The combination of 5-fluorouracil (5-FU)/leucovorin (LV) plus oxaliplatin significantly improves disease-free survival in Dukes B/Stage II and Dukes C/Stage III, and improves overall survival in Dukes C/Stage III compared to 5-FU/LV alone, as reported by the American Society of Clinical Oncology 1, 3
Capecitabine has been shown to be at least as effective as, and less toxic than, bolus 5-FU/LV, according to the European Society for Medical Oncology 1, 3

Regular follow-up is essential to detect recurrence that may be amenable to salvage surgery, as recommended by the American Cancer Society 1, 3
Recommended follow-up includes colonoscopy at year 1 and every 3-5 years thereafter, liver ultrasonography every 6 months for 3 years and after years 4 and 5, CT scan of chest and abdomen for 3 years in high-risk patients, and tumor marker determination every 3-6 months for 3 years and every 6-12 months in years 4 and 5 if initially elevated 1, 3

Inadequate lymph node sampling (<12 nodes) can lead to understaging and inappropriate treatment decisions, as warned by the College of American Pathologists 2, 5
Failing to assess mismatch repair/microsatellite instability status in Dukes B/Stage II colon cancer can lead to suboptimal treatment decisions, according to the American Society of Clinical Oncology 5
Patients with multiple high-risk features in Dukes B/Stage II have worse outcomes and should be strongly considered for adjuvant chemotherapy, as recommended by the National Comprehensive Cancer Network 5